Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli

Journal of Infectious Diseases

Volumn 209, Issue 10, 2014, Pages 1551-1561

  Wacker, Michael ^a   Wang, Linhui ^b,c   Kowarik, Michael ^a   Dowd, Meghan ^b   Lipowsky, Gerd ^a   Faridmoayer, Amir ^a   Shields, Kelly ^b   Park, Saeyoung ^b   Alaimo, Cristina ^a   Kelley, Kathryn A ^b   Braun, Martin ^a   Quebatte, Julien ^a   Gambillara, Veronica ^a   Carranza, Paula ^a   Steffen, Michael ^a   Lee, Jean C ^b  

^a GlycoVaxyn AG   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

animal infection models; bacteremia; bioconjugate vaccine; capsular polysaccharides; glycoengineering.; glycoprotein; pneumonia; Staphylococcus aureus

Indexed keywords

BACTERIAL POLYSACCHARIDE; BACTERIUM ANTIBODY; STAPHYLOCOCCUS VACCINE;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; INFECTION PREVENTION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTECTION; PROTEIN ENGINEERING; RABBIT; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS INFECTION; VACCINATION; VACCINE PRODUCTION;

ANIMAL INFECTION MODELS; BACTEREMIA; BIOCONJUGATE VACCINE; CAPSULAR POLYSACCHARIDES; GLYCOENGINEERING; GLYCOPROTEIN; PNEUMONIA; STAPHYLOCOCCUS AUREUS;

ANIMALS; BACTERIAL PROTEINS; ESCHERICHIA COLI; GENE EXPRESSION REGULATION, BACTERIAL; GLYCOCONJUGATES; GLYCOPROTEINS; HUMANS; MICE; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; VACCINES, SYNTHETIC;

EID: 84899056813     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit800     Document Type: Article

References (38)

1. Bassetti M, Nicco E, Mikulska M. Why is community-associated MRSA spreading across the world and how will it change clinical practice? Int J Antimicrob Agents 2009; 34 (Suppl 1):S15-9.
2. Bradley SF. Staphylococcus aureus pneumonia: emergence of MRSA in the community. Semin Respir Crit Care Med 2005; 26:643-9.
3. Chambers HF. Community-associated MRSA-resistance and virulence converge. N Engl J Med 2005; 352:1485-7.
4. Shinefield H, Black S, Fattom A, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002; 346:491-6.
5. Broughan J, Anderson R, Anderson AS. Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines. Expert Rev Vaccines 2011; 10:695-708.
6. Fowler VG, Allen KB, Moreira ED, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 2013; 309:1368-78.
7. Proctor RA. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis 2012; 54:1179-86.
8. Thakker M, Park J-S, Carey V, Lee JC. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun 1998; 66:5183-9.
9. Watts A, Ke D, Wang Q, Pillay A, Nicholson-Weller A, Lee JC. Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect Immun 2005; 73:3502-11.
10. Bhakdi S, Tranum-Jensen J. Alpha-toxin of Staphylococcus aureus. Microbiol Rev 1991; 55:733-51.
11. Menzies BE, Kernodle DS. Site-directed mutagenesis of the alpha-toxin gene of Staphylococcus aureus: role of histidines in toxin activity in vitro and in a murine model. Infect Immun 1994; 62:1843-7.
12. Kennedy AD, Bubeck Wardenburg J, Gardner DJ, et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J Infect Dis 2010; 202: 1050-8.
13. Wardenburg JB, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008; 205:287-94.
14. Rauch S, DeDent AC, Kim HK, Bubeck Wardenburg J, Missiakas DM, Schneewind O. Abscess formation and alpha-hemolysin induced toxicity in a mouse model of Staphylococcus aureus peritoneal infection. Infect Immun 2012; 80:3721-32.
15. Wacker M, Linton D, Hitchen PG, et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 2002; 298:1790-3.
16. Feldman MF, Wacker M, Hernandez M, et al. Engineering Nlinked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA 2005; 102:3016-21.
17. Wetter M, Kowarik M, Steffen M, Carranza P, Corradin G, Wacker M. Engineering, conjugation, and immunogenicity assessment of Escherichia coli O121 O antigen for its potential use as a typhoid vaccine component. Glycoconj J 2013; 30:511-22.
18. Ihssen J, Kowarik M, Dilettoso S, Tanner C, Wacker M, Thony-Meyer L. Production of glycoprotein vaccines in Escherichia coli. Microb Cell Fact 2010; 9:61.
19. Killeen KP, Collier RJ. Conformational integrity of a recombinant toxoid of Pseudomonas aeruginosa exotoxin A containing a deletion of glutamic acid-553. Biochim Biophys Acta 1992; 1138:162-6.
20. Kowarik M, Young NM, Numao S, et al. Definition of the bacterial N-glycosylation site consensus sequence. EMBO J 2006; 25:1957-66.
21. Jursch R, Hildebrand A, Hobom G, et al. Histidine residues near the N terminus of staphylococcal alpha-toxin as reporters of regions that are critical for oligomerization and pore formation. Infect Immun 1994; 62:2249-56.
22. Duthie ES, Lorenz LL. Staphylococcal coagulase; mode of action and antigenicity. J Gen Microbiol 1952; 6:95-107.
23. Linde H, Wagenlehner F, Strommenger B, et al. Healthcare-associated outbreaks and community-acquired infections due to MRSA carrying the Panton-Valentine leucocidin gene in southeastern Germany. Eur J Clin Microbiol Infect Dis 2005; 24:419-22.
24. Voyich JM, OttoM,Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 2006; 194:1761-70.
25. BubeckWardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis 2008; 198:1166-70.
26. Park S, Kelley KA, Vinogradov E, et al. Characterization of the structure and biological functions of a capsular polysaccharide produced by Staphylococcus saprophyticus. J Bacteriol 2010; 192:4618-26.
27. Burton RL, Nahm MH. Development of a fourfold multiplexed opsonophagocytosis assay for pneumococcal antibodies against additional serotypes and discovery of serological subtypes in Streptococcus pneumoniae serotype 20. Clin Vaccine Immunol 2012; 19:835-41.
28. Gray BM. ELISA methodology for polysaccharide antigens: protein coupling of polysaccharides for adsorption to plastic tubes. J Immunol 1979; 28:187-92.
29. Bugg TD, Brandish PE. From peptidoglycan to glycoproteins: common features of lipid-linked oligosaccharide biosynthesis. FEMS Microbiol Lett 1994; 119:255-62.
30. Wacker M, Casimiro DR. Synthesizing vaccines with microbes. In: von Gabain A, Klade C, eds. Development of novel vaccines. Wien: Springer-Verlag, 2012:125-45.
31. Dean CR, Franklund CV, Retief JD, et al. Characterization of the serogroup O11 O-antigen locus of Pseudomonas aeruginosa PA103. J Bacteriol 1999; 181:4275-84.
32. Jones C. Revised structures for the capsular polysaccharides from Staphylococcus aureus types 5 and 8, components of novel glycoconjugate vaccines. Carbohydr Res 2005; 340:1097-106.
33. Ragle BE, Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 2009; 77:2712-8.
34. Daum RS, Spellberg B. Progress toward a Staphylococcus aureus vaccine. Clin Infect Dis 2012; 54:560-7.
35. Schaffer AC, Lee JC. Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am 2009; 23:153-71.
36. Lin L, Ibrahim AS, Xu X, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 2009; 5:e1000703.
37. Joshi A, Pancari G, Cope L, et al. Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis model. Hum Vaccin Immunother 2012; 8:336-46.
38. Narita K, Hu DL, Mori F, Wakabayashi K, Iwakura Y, Nakane A. Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogenbinding domain of clumping factor A. Infect Immun 2010; 78: 4234-42.